[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![Apogee Therapeutics, Inc. Common Stock Graphic](https://lunarcrush.com/gi/w:26/t:$apge.png) Apogee Therapeutics, Inc. Common Stock (APGE)

Apogee Therapeutics (APGE) surges after closing a public offering and positive analyst ratings. Investors are excited about the potential of its eczema drugs as a rival to Dupixent.

### About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. Common Stock (APGE) is a publicly traded stock in the healthcare sector.  
Apogee Therapeutics, Inc. Common Stock uses the ticker $APGE for trading. Listed in the [Stocks](/list/stocks) and  category.

### Insights [#](/topic/$apge/insights)
- Apogee Therapeutics, Inc. Common Stock (APGE) market cap is up XX% from the previous X months.
- Apogee Therapeutics, Inc. Common Stock (APGE) social dominance is up XXXXX% from the previous week.
- Apogee Therapeutics, Inc. Common Stock (APGE) galaxy score™ is up XXXXXX% from the previous month.

### Price: $XXXXX [#](/topic/$apge/close)
---
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$apge/time-series/close.tsv)  
The price action is likely driven by a combination of positive analyst ratings, the closing of a public offering, and the potential of its eczema drugs. The initial price drop after the offering was short-lived, and the stock has since recovered, indicating strong investor confidence.  

| 24-Hour | 7-Day | 30-Day |
| ------- | ----- | ------ |
| XXXX%   | XXXX% | XXXXX% |

**1-Year High**: $XXXXX on 2024-11-08  
**1-Year Low**: $XXXXX on 2025-04-08  
  
  
### AltRank: XXXXX [#](/topic/$apge/alt_rank)
---
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$apge/time-series/alt_rank.tsv)  
Apogee Therapeutics, Inc. Common Stock (APGE) is currently AltRank #1,745 based on combined combined social and market metrics
**Daily Average**: XXXXX  
**1 Week**: XXX +740  
**1 Month**: XXXXX -XXX  
**6 Months**: XXXXX +1,486  
**1 Year**: XXXXX +900  
**1-Year High**: XXXXX on 2025-09-19  
**1-Year Low**: XX on 2025-02-17  
  
  
### Galaxy Score: XXXXX [#](/topic/$apge/galaxy_score)
---
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$apge/time-series/galaxy_score.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XX  
**1 Week**: XX +15  
**1 Month**: XX +47  
**6 Months**: XX -X  
**1 Year**: XX +34  
**1-Year High**: XX on 2025-10-08  
**1-Year Low**: XX on 2025-02-11  
  
  
### Engagements: XXXXX [#](/topic/$apge/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$apge/time-series/interactions.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XXXXX  
**1 Week**: XXXXXX -XX%  
**1 Month**: XXXXXXX +102%  
**6 Months**: XXXXXXXXX +117%  
**1 Year**: XXXXXXXXX +90%  
**1-Year High**: XXXXXXX on 2025-07-07  
**1-Year Low**: XXX on 2024-11-06  

| Social Network | X     |
| -------------- | -     |
| Engagements    | XXXXX |
  

  
  
### Mentions: XX [#](/topic/$apge/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$apge/time-series/posts_active.tsv)  
**Current Value**: XX  
**Daily Average**: XX  
**1 Month**: XX -XX%  
**6 Months**: XXXXX +81%  
**1 Year**: XXXXX +197%  
**1-Year High**: XXX on 2025-07-07  
**1-Year Low**: XX on 2025-09-06  

| Social Network | X   |
| -------------- | -   |
| Mentions       | XXX |
  

  
  
### Creators: XX [#](/topic/$apge/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$apge/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning Apogee Therapeutics, Inc. Common Stock (APGE) in the last XX hours which is up XX% from XX in the previous XX hours
**Daily Average**: XX  
**1 Month**: XX -XX%  
**6 Months**: XXXXX +234%  
**1 Year**: XXXXX +233%  
**1-Year High**: XXX on 2025-07-07  
**1-Year Low**: X on 2025-09-06  

The most influential creators that mention Apogee Therapeutics, Inc. Common Stock in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)           | X    | XXXXX     | X     | XXXXX       |
| [@HOThomasWPhelps](/creator/twitter/HOThomasWPhelps) | X    | XXXXX     | X     | XXXXX       |
| [@JoseRestonVA](/creator/twitter/JoseRestonVA)       | X    | XXXXX     | X     | XXX         |
| [@MSollender](/creator/twitter/MSollender)           | X    | XXXXXX    | X     | XXX         |
| [@HenryHarris666](/creator/twitter/HenryHarris666)   | X    | XXXXX     | X     | XX          |
| [@Biotech2k1](/creator/twitter/Biotech2k1)           | X    | XXXXXX    | X     | XX          |
| [@BuyTheUgly](/creator/twitter/BuyTheUgly)           | X    | XX        | X     | XX          |
| [@Brad_E_Schulz](/creator/twitter/Brad_E_Schulz)     | X    | XXXXXX    | X     | X           |
| [@seedy19tron](/creator/twitter/seedy19tron)         | X    | XXXXX     | X     | X           |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA)     | XX   | XXXXX     | X     | X           |

[View More](/list/creators/$apge/100)
  
  
### Sentiment: XX% [#](/topic/$apge/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$apge/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% -XX%  
**1 Month**: XX% -XX%  
**6 Months**: XX% -XX%  
**1 Year**: XX% +15%  
**1-Year High**: XXX% on 2024-10-21  
**1-Year Low**: X% on 2025-01-28  

**Most Supportive Themes**
- **Positive Analyst Ratings and Price Targets:** (35%) Several analysts have reiterated 'Buy' ratings and provided positive price targets for APGE, contributing to positive sentiment.
- **Closing of Public Offering:** (25%) The announcement of the closing of a public offering and the exercise of the underwriters' option to purchase additional shares has been met with positive reactions.
- **Potential Dupixent Rivalry:** (20%) TD Cowen highlighted APGE's eczema drugs as potential rivals to Dupixent, which has generated significant interest.
  
**Most Critical Themes**
- **Public Offering Concerns:** (10%)  The public offering, while closed, initially caused a price drop, indicating some investor concern.
- **After-Hours Price Drop:** (10%)  The stock experienced a price decrease after the announcement of the public offering, which may be a concern for some investors.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXXXX    | XX% | XXXXX   | XX% | XXX      | X% |
|         |          |     |         |     |          |    |
| Total   | XXXXX    | XX% | XXXXX   | XX% | XXX      | X% |
  

  
  
### Social Dominance: XXXXXXX% [#](/topic/$apge/social_dominance)
---
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$apge/time-series/social_dominance.tsv)  
**Current Value**: XXXXXXX%  
**Daily Average**: XXXXX%  
**1 Week**: XXXXXX% +0.001%  
**1 Month**: XXXXXX% -XXXXX%  
**6 Months**: XXXXXX% -XXXXXX%  
**1 Year**: XXXXXX% -XXXXX%  
**1-Year High**: XXXXX% on 2025-07-07  
**1-Year Low**: XXXXXX% on 2025-10-19  
  
  
### Market Dominance: XXXXXXX% [#](/topic/$apge/market_dominance)
---
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$apge/time-series/market_dominance.tsv)  
**Current Value**: XXXXXXX%  
**Daily Average**: X%  
**1-Year High**: XXXXXXX% on 2024-11-08  
**1-Year Low**: XXXXXXX% on 2025-02-27  
  
  
### Market Cap: $XXXXXXXXXXXXX [#](/topic/$apge/market_cap)
---
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$apge/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$apge/time-series/market_cap.tsv)  
**Current Value**: $XXXXXXXXXXXXX  
**Daily Average**: $XXXXXXXXXXXXX  
**1 Week**: $XXXXXXXXXXXXX +$23%  
**1 Month**: $XXXXXXXXXXXXX +$71%  
**6 Months**: $XXXXXXXXXXXXX +$80%  
**1 Year**: $XXXXXXXXXXXXX +$23%  
**1-Year High**: $XXXXXXXXXXXXX on 2025-10-15  
**1-Year Low**: $XXXXXXXXXXXXX on 2025-04-08  

**Top assets mentioned**
In the posts about Apogee Therapeutics, Inc. Common Stock in the last XX hours

[Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr)
[Akropolis (AKRO)](/topic/$akro)
[Sanofi (SNY)](/topic/sanofi)
[uniQure N.V. (QURE)](/topic/$qure)
[Avidity Biosciences, Inc. Common Stock (RNA)](/topic/$rna)
[Applied Blockchain, Inc. Common Stock (APLD)](/topic/$apld)
[AbbVie Inc (ABBV)](/topic/$abbv)
[Intellia Therapeutics, Inc (NTLA)](/topic/$ntla)
[Merus N.V. Common Shares (MRUS)](/topic/$mrus)

**Top topics mentioned**
In the posts about Apogee Therapeutics, Inc. Common Stock in the last XX hours

[$kymr](/topic/$kymr), [$nktr](/topic/$nktr), [$crvs](/topic/$crvs), [stocks healthcare](/topic/stocks-healthcare), [$akro](/topic/$akro), [sanofi](/topic/sanofi), [stocks](/topic/stocks), [$qure](/topic/$qure), [$rna](/topic/$rna), [$apld](/topic/$apld), [$abbv](/topic/$abbv), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$ntla](/topic/$ntla), [$mrus](/topic/$mrus), [regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc), [$regn](/topic/$regn), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [bitfarms](/topic/bitfarms), [over the](/topic/over-the), [stocks technology](/topic/stocks-technology), [$path](/topic/$path), [investment](/topic/investment), [$mdgl](/topic/$mdgl), [$idya](/topic/$idya), [$bbio](/topic/$bbio), [stocks industrials](/topic/stocks-industrials), [$vera](/topic/$vera), [$alec](/topic/$alec), [$algs](/topic/$algs), [$allk](/topic/$allk), [$allr](/topic/$allr), [stocks bitcoin miners](/topic/stocks-bitcoin-miners), [$run](/topic/$run), [$nne](/topic/$nne), [approved](/topic/approved), [$prgo](/topic/$prgo), [$cort](/topic/$cort), [$pcvx](/topic/$pcvx), [$ptct](/topic/$ptct), [primary market](/topic/primary-market), [$abvx](/topic/$abvx), [$oklo](/topic/$oklo), [$hsbc](/topic/$hsbc), [$asts](/topic/$asts), [biogen inc](/topic/biogen-inc), [$biib](/topic/$biib), [$cytk](/topic/$cytk), [coins defi](/topic/coins-defi), [$telo](/topic/$telo), [$ngne](/topic/$ngne), [monaco](/topic/monaco), [$barcl](/topic/$barcl), [$14b](/topic/$14b), [$lyel](/topic/$lyel), [coins base ecosystem](/topic/coins-base-ecosystem), [pill](/topic/pill), [$allo](/topic/$allo), [stocks crypto treasuries](/topic/stocks-crypto-treasuries), [$trip](/topic/$trip), [$ddog](/topic/$ddog), [$eose](/topic/$eose), [stocks energy](/topic/stocks-energy), [cipher mining](/topic/cipher-mining), [$mur](/topic/$mur), [1m](/topic/1m), [$cadl](/topic/$cadl), [$clpt](/topic/$clpt), [$hl](/topic/$hl), [$joby](/topic/$joby), [$mfh](/topic/$mfh), [$qubt](/topic/$qubt), [$qbts](/topic/$qbts), [$race](/topic/$race), [$odd](/topic/$odd), [akro akero therapeutics inc](/topic/akro-akero-therapeutics-inc), [$scyx](/topic/$scyx), [$46m](/topic/$46m), [$10m](/topic/$10m), [$20m](/topic/$20m), [china](/topic/china), [$llc](/topic/$llc), [$arwr](/topic/$arwr), [$rytm](/topic/$rytm), [$syre](/topic/$syre), [$orka](/topic/$orka), [$jbio](/topic/$jbio), [$cbio](/topic/$cbio), [leo](/topic/leo), [jersey](/topic/jersey), [$28b](/topic/$28b), [launches](/topic/launches), [dominance](/topic/dominance), [$adma](/topic/$adma), [$mtsr](/topic/$mtsr), [$ions](/topic/$ions), [$pmax](/topic/$pmax), [$abus](/topic/$abus), [$amlx](/topic/$amlx), [$atyr](/topic/$atyr), [$agio](/topic/$agio)

### Top Social Posts [#](/topic/$apge/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"@HOThomasWPhelps @JoseRestonVA @basadomente I am not competent to answer this question. Still learning about the space from you @JoseRestonVA @A_May_MD and Grok I personally have solid position in $NKTR (from 0.5c converted to shares at expiration) and moderate in $KYMR via ITMs Based on grok review I may open one in $APGE"  
[X Link](https://x.com/Andre_AGTC/status/1979914080996512159) [@Andre_AGTC](/creator/x/Andre_AGTC) 2025-10-19T14:14Z 6072 followers, XXX engagements


"See below grok comparison on MOA and POS in the AtD market and dominance over dipixent Pobability / Dominance $APGE (NP) High /High MC 3.7B $NKTR Moderate / High MC 1.1B $KYMR Moderate / High MC 4.3B $CRVS (NP) Mod-Low / Mod-Low 0.5B"  
[X Link](https://x.com/Andre_AGTC/status/1979912133992194112) [@Andre_AGTC](/creator/x/Andre_AGTC) 2025-10-19T14:06Z 6072 followers, 4118 engagements


"@JoseRestonVA @HOThomasWPhelps @basadomente Grok thinks that $APGE has highest probability to succeed against dupi - proven moa with dosing advantage $NKTR good probability new MOA but still injectable $KYMR good probability disease modifying MOA ORAL but early $CRVS low probability dark horse"  
[X Link](https://x.com/Andre_AGTC/status/1979908291955175691) [@Andre_AGTC](/creator/x/Andre_AGTC) 2025-10-19T13:51Z 6072 followers, 4710 engagements


"Agreed. At this current stage it is hard to make any overvaluation claim on any of these companies especially considering how massive the TAM is on AtD (and other related conditions). Regarding $APGE its EV is $2.8b approx (including the recent secondary that took only X days to close). Even if APG777 (or 279) do not end up better than Dupi given the strong launches of EBGLYSS and Nemluvio that valuation is still constructive. The same (or even better) can be said of NKTR CRVS or others but each carry their own set of risks / opportunities. CRVS is still early in development stage. Maybe"  
[X Link](https://x.com/JoseRestonVA/status/1979875212511395852) [@JoseRestonVA](/creator/x/JoseRestonVA) 2025-10-19T11:40Z 2929 followers, XXX engagements